Scholars Central

Conference abstractPublished 11 Oct 2019

Gene Silencing Approach for an orphan GNAO1-related neurodevelopmental disorder

Authors: Maryana Bardina, Anna Polikarpova, Elizaveta Loseva, Svetlana Vassilieva, Tatiana Egorova

Marlin Biotech LLC, RussiaInstitute of Gene Biology-RAS, Russia

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

GNAO1 disorder is a fatal genetic neurodevelopmental disease characterized by epilepsy and movement impairment that begins in early infancy. GNAO1 gene is highly expressed in the brain and certain de novo mutations in this gene result in production of toxic protein that causes dysregulation in neuronal signaling. Currently no effective treatment is available for this pathology. Our aim at Marlin Biotech is to find gene therapy cure for GNAO1 disorder. Considering autosomal dominant condition of this disease, we suggest a strategy of allele-specific gene suppression that would selectively lower levels of abnormal protein in the brain neurons and leave functional protein unaffected. To test gene therapy approach in vitro, we developed an assay with expression of exogenous wild type or mutant (c.607 G>A) GNAO1 variants in cultured cells. We screened synthetic siRNA duplexes that target mutation site in GNAO1 RNA and downregulate expression of mutated gene through RNA interference (RNAi) pathway. Our data demonstrates that two RNAi effectors reduce accumulation of mutant GNAO1 transcripts in allele-specific manner. These results were confirmed at RNA and protein levels in heterozygous assay where both wild type and mutant GNAO1 variants were introduced into cells simultaneously in 1:1 ratio to mimic heterozygous condition of the patients. Taken together, our pilot experiments demonstrate the potential of allele-specific silencing approach for gene therapy of GNAO1-related neurodevelopmental disorder. Our next step is designing RNAi-based therapeutics for GNAO1 disorder that is compatible with delivery via adeno-associated virus (AAV) vectors to brain tissues. To validate beneficial effect of AAV-RNAi technology in vivo, we are also developing humanized mouse model of GNAO1 disorder using CRISPR/Cas9 technology.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Clinical Infectious Diseases & Practice.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Clinical Infectious Diseases & Practice
  • SubjectInfectious Diseases
  • BylineArticles whose byline prints “Maryana Bardina”
  • BylineArticles whose byline prints “Anna Polikarpova”
  • BylineArticles whose byline prints “Elizaveta Loseva”
  • BylineArticles whose byline prints “Svetlana Vassilieva”
  • BylineArticles whose byline prints “Tatiana Egorova”